Abdul Rafae

400 total citations
34 papers, 256 citations indexed

About

Abdul Rafae is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Abdul Rafae has authored 34 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 14 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Abdul Rafae's work include Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (9 papers) and Peptidase Inhibition and Analysis (4 papers). Abdul Rafae is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (9 papers) and Peptidase Inhibition and Analysis (4 papers). Abdul Rafae collaborates with scholars based in United States, Pakistan and India. Abdul Rafae's co-authors include Hamid Ehsan, Ahsan Wahab, Faiz Anwer, Seren Durer, Ceren Durer, Kamran Mushtaq, Ahmad Kamal, Faisal Kamiran, Chakra P. Chaulagain and Jason Valent and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Frontiers in Oncology.

In The Last Decade

Abdul Rafae

29 papers receiving 252 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abdul Rafae United States 8 133 119 84 38 33 34 256
Marta Sonia González Spain 11 116 0.9× 62 0.5× 124 1.5× 61 1.6× 17 0.5× 38 280
Koichi Onodera Japan 11 79 0.6× 67 0.6× 63 0.8× 64 1.7× 38 1.2× 38 264
Susanne Strifler Germany 8 243 1.8× 179 1.5× 189 2.3× 29 0.8× 20 0.6× 16 345
Amandeep Godara United States 8 60 0.5× 86 0.7× 137 1.6× 31 0.8× 10 0.3× 50 259
Ga‐Young Song South Korea 9 59 0.4× 103 0.9× 34 0.4× 17 0.4× 31 0.9× 33 204
Razan Mohty United States 10 80 0.6× 149 1.3× 52 0.6× 33 0.9× 9 0.3× 43 257
Lihui Shi China 10 214 1.6× 129 1.1× 133 1.6× 103 2.7× 6 0.2× 23 315
Pierre‐Marie Morice France 7 35 0.3× 243 2.0× 97 1.2× 22 0.6× 22 0.7× 21 382
Sreekanth Reddy United States 6 47 0.4× 178 1.5× 72 0.9× 24 0.6× 9 0.3× 11 289
Depei Wu China 8 174 1.3× 98 0.8× 60 0.7× 57 1.5× 4 0.1× 55 281

Countries citing papers authored by Abdul Rafae

Since Specialization
Citations

This map shows the geographic impact of Abdul Rafae's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdul Rafae with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdul Rafae more than expected).

Fields of papers citing papers by Abdul Rafae

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abdul Rafae. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdul Rafae. The network helps show where Abdul Rafae may publish in the future.

Co-authorship network of co-authors of Abdul Rafae

This figure shows the co-authorship network connecting the top 25 collaborators of Abdul Rafae. A scholar is included among the top collaborators of Abdul Rafae based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdul Rafae. Abdul Rafae is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rafae, Abdul, Muhammad Khawar Sana, Ahmed Ibrahim, et al.. (2022). Electrolyte Abnormalities Associated With The Use of Atezolizumab – A Systematic Review. Journal of Community Hospital Internal Medicine Perspectives. 12(2). 35–44. 2 indexed citations
3.
Abdelazeem, Basel, et al.. (2022). Restrictive versus Liberal Blood Transfusion Strategy in Patients With Acute Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials. Journal of Community Hospital Internal Medicine Perspectives. 12(3). 40–47. 4 indexed citations
4.
Rafae, Abdul, Hamid Ehsan, Ahsan Wahab, et al.. (2022). Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients. Critical Reviews in Oncology/Hematology. 176. 103744–103744. 3 indexed citations
5.
Abdelazeem, Basel, Kirellos Said Abbas, Bilal Haider Malik, et al.. (2022). The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials. Expert Review of Anticancer Therapy. 22(10). 1127–1140. 6 indexed citations
6.
Ehsan, Hamid, et al.. (2021). Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. Clinical Lymphoma Myeloma & Leukemia. 22(5). e285–e292. 1 indexed citations
7.
Wahab, Ahsan, et al.. (2021). Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Frontiers in Oncology. 11. 678634–678634. 60 indexed citations
8.
Ehsan, Hamid, et al.. (2021). Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma. Journal of Hematology. 10(3). 89–97. 5 indexed citations
9.
Rafae, Abdul, et al.. (2021). Early presentation of pembrolizumab-associated pneumonitis. BMJ Case Reports. 14(7). e242493–e242493. 3 indexed citations
10.
Ehsan, Hamid, Ahsan Wahab, Abdul Rafae, et al.. (2021). Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. OncoTargets and Therapy. Volume 14. 4941–4960. 6 indexed citations
11.
Rafae, Abdul, Ahsan Wahab, Hamid Ehsan, et al.. (2021). Recent updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory multiple myeloma.. Journal of Clinical Oncology. 39(15_suppl). e20034–e20034. 7 indexed citations
12.
Iftikhar, Raheel, Tariq Ghafoor, Mehreen Ali Khan, et al.. (2020). Allogeneic hematopoietic stem cell transplant in rare hematologic disorders: a single center experience from Pakistan. Bone Marrow Transplantation. 56(4). 863–872. 2 indexed citations
13.
Iftikhar, Raheel, Faiz Anwer, Abdul Rafae, et al.. (2020). Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Reviews. 47. 100772–100772. 41 indexed citations
14.
Ahmed, Zahoor, Rabia Ashraf, Moazzam Shahzad, et al.. (2020). Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Ineligible Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. Blood. 136(Supplement 1). 32–33. 1 indexed citations
15.
16.
Durer, Ceren, Seren Durer, Sarah Lee, et al.. (2019). Treatment of relapsed multiple myeloma: Evidence-based recommendations. Blood Reviews. 39. 100616–100616. 42 indexed citations
17.
Iftikhar, Ahmad, Patrick Campbell, Abdul Rafae, et al.. (2019). A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients. Infectious Diseases in Clinical Practice. 28(1). 10–15. 3 indexed citations
18.
19.
Khan, Ali Younas, Muhammad Junaid Tariq, Muhammad Usman, et al.. (2018). Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review. Blood. 132(Supplement 1). 2025–2025. 2 indexed citations
20.
Rafae, Abdul, Ali Younas Khan, Ceren Durer, et al.. (2018). Diagnostic and Prognostic Role of Fecal Calprotectin As a Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature. Blood. 132(Supplement 1). 5725–5725.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marta Sonia González Breakdown of academic impact, for papers by Koichi Onodera Breakdown of academic impact, for papers by Susanne Strifler Breakdown of academic impact, for papers by Amandeep Godara Breakdown of academic impact, for papers by Ga‐Young Song Breakdown of academic impact, for papers by Razan Mohty Breakdown of academic impact, for papers by Lihui Shi Breakdown of academic impact, for papers by Pierre‐Marie Morice Breakdown of academic impact, for papers by Sreekanth Reddy Breakdown of academic impact, for papers by Depei Wu
Rankless by CCL
2026